Oncology therapy developer A2 Biotherapeutics raised $71.5m from investors including Hartford HealthCare Endowment to take its funding to $136m altogether.

A2 Biotherapeutics, a US-based developer of cell therapies for the treatment of solid tumours, has closed a $71.5m series B round featuring Hartford HealthCare Endowment, the philanthropic arm of healthcare provider Hartford HealthCare.

Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital and Euclidean Capital also took part in the round along with UC Investments, part of University of California’s Office of the Chief Investment Officer of the Regents.

Founded in 2018, A2 is working on cell therapies designed…